The hemodynamic, cerebrovascular, and neu rologic effects of hypercapnia with 4% and 6% CO2 were retrospectively reviewed in 217 patients referred for re gional CBF (rCBF) procedures. Inhalation of CO2 signif icantly increased rCBF, blood pressure, and pulse from baseline. The findings suggest a higher incidence of side
Examination of hypercapnic changes in regional CBF (rCBF) has provided critical information on the functional integrity of the cerebrovascular cir culation, as well as insight into the etiology and pathogenesis of several cerebrovascular disorders (Bullock et aI. , 1985; Fox et aI., 1988; Tatemichi et aI., 1988 Tatemichi et aI., , 1990 Prohovnik et aI. , 1989) . However, CO2 can produce adverse effects, including CNS complaints, hypertension, tachypnea, and adverse myocardial oxygen balance (Hardgrove et aI. , 1938; Dripps and Comroe, 1947; Cullen and Eger, 1974; Rasmussen et aI. , 1978 ; Woods et aI. , 1988) . De spite these actions, scant attention has been paid to the safety profile of CO2, Early literature docu mented the effects of CO2 primarily in young, healthy subjects (Dripps and Comroe, 1947; Cullen and Eger, 1974; Woods et aI. , 1988) . These pub lished effects may not be sufficient to predict prob lems in elderly patients with cerebrovascular anom alies and cardiac or respiratory compromise. effects with 6% CO2 concentration and an equivalent va soreactivity to 4%. We recommend the use of 4% CO2 for hypercapnic stimulation, and present safety guidelines for its use. Key Words: Carbon dioxide-Hypercapnia, ad verse effects-Hemodynamics-133Xe-rCBF-Cerebral circulation.
We have had the unique opportunity to document cerebrovascular and peripheral hemodynamic ef fects of CO2 in 217 patients with a variety of cere brovascular and medical disorders. The present pa per is a retrospective review of these data with par ticular attention to adverse effects of CO2 inhalation in awake patients, and a theoretical discussion of possible side effects.
METHODS
Laboratory records of all patients referred to the Brain Imaging Division for rCBF from 1984 to January 1989 were reviewed. A complete set of data was available from 217 patients, including: CO2, blood pressure, blood flow and timing data, and sufficient clinical history. Patients had been clinically referred for a variety of disorders, or had been part of a research protocol (Table 1) . Only one paired set of runs were included for each patient. Patients with intracerebral hematoma or hemorrhagic infarction within the prior 1 month, myocardial infarction within 6 months, unstable angina, life-threatening ventricular ar rhythmias, or severe chronic obstructive pulmonary dis ease (Pac02 > 50 or oxygen use) were not accepted for hypercapnic challenge.
All rCBF measurements employed the I33Xe inhalation technique using the Novo Cerebrograph 32c, and were performed as previously described (Maximilian et aI., 1980) . Hypercapnic sessions always required a 5-min re maining activity period. Three minutes into this period patients were switched to breathing the CO2 mixture. Due to limitations in the breathing circuit of the cerebrograph, CO2 was turned off during Xe inhalation and restarted after this I-min period for the remainder of the study. Runs were considered adequate if CO2 inhalation lasted at least 1.5 min after the start of Xe administration. End tidal CO2 (P etC02) typically returned to a steady state within 30 s following the end of the Xe inhalation period (Prohovnik, unpublished observations) .
Occasionally during hypercapnic challenge, CO2 was discontinued based on the following ad hoc criteria: (a) Systolic blood pressure (SBP) > 190 or >30 above nor mocapnic levels. (b) Diastolic blood pressure (DBP) > 110 or >20 above normocapnic levels. (c) Pulse rate >20 above normocapnic levels. (d) Patient complaint of respi ratory discomfort, chest pain, or neurologic symptoms. Depending on the clinical situation, the first three guide lines served only as relative contraindications, whereas CO2 was always discontinued when patients reported symptoms. These guidelines were formulated by us in 1984 based on a priori clinical assumptions at that time.
Baseline SBP, DBP, and pulse (vital signs) were taken immediately after the baseline run had completed; during the hypercapnic run, vital signs were taken approxi mately every 2-3 min, and the data set with the highest SBP reading was used in the current analysis. Petco2 was recorded continuously during each run by means of a capnograph hooked to the breathing circuit. The visual average of this graph is reported as P etCo2' We employed P etC02 as a valid estimate of P ac02 given our exclusion of patients with severe chronic obstructive pulmonary dis ease (Moon and Camporesi, 1990) ; good agreement has also been shown between these measures during general anesthesia (Young et aI., 1990) .
Data Analysis
All data were evaluated with standard quality control measures and analyzed using the six unknown model (Prohovnik et aI., 1983) . Flow is pre sented as the initial slope index (lSI) and represents the average of all 32 detectors (Risberg et aI., 1975; Pro hovnik et aI., 1985) . During earlier studies, 6% CO2 was utilized for an initial evaluation; based on that brief clin ical experience, it was abandoned in favor of 4%. Despite the small sample size, the 6% group was included for formal analysis. The analysis consisted of an analysis of variance on change scores of all variables (hypercapnic versus normocapnic), with inhaled CO2 concentration (4% versus 6%) and a history of hypertension (present versus absent) as between-subject grouping variables; gender was equally distributed and did not exert signifi cant influence on any outcome measure. Hypertension was defined as present when specifically reported on the clinical referral form, or if antihypertensive medications were listed.
RESULTS
Patient information and baseline hemodynamic characteristics are given in Table 2 for patients who underwent 4% (n = 200) and 6% (n = 17) CO2 inhalation.
Overall, CO2 administration increased P etC02 (p < 0.000 1) and flow (p < 0.0002) compared with baseline. The P etC02 elevation (all patients in creased by �2 mm Hg) was affected by the inhaled CO2 concentration (F1,216 = 53.5, P < 0.000 1): Flow (lSI units) similarly increased 6.4 ± 4.3 for 4% versus 9.5 ± 8. 1 for 6% (F1•216 = 7.0, P < 0.009).
The presence of hypertension did not significantly affect increases in flow, nor was there a significant interaction between a history of hypertension and the level of CO2 employed. Due to pulmonary function variability (among other factors), inhalation of a given CO2 concentra- tion does not raise Petco2 by a constant amount across subjects (the coefficient of variation in the Petco2 change was �30%). Flow changes were therefore expressed in relation to the change in Petco2, i.e., by reactivity. We computed reactivity in absolute terms (� lSI units per � mm Hg) as well as percent reactivity (� lSI units per resting lSI per � mm Hg). The mean values of the two indices were 0.9 1 and 2. 1, respectively, with no significant effect of inhaled CO2 concentration or hypertension. The effects of CO2 and hypertension on vital signs were complex ( Table 3 ). The change of SBP was greater for hypertensive patients (20.4 versus 13.5 mm Hg, Fl•2l3 = 13.5, P = 0.0003). The change in DBP was greater for hypertensive sub jects (l0.4 versus 7.3 mm Hg, Fl,213 = 6.86, P < 0.01), and was greater with 6% CO2 (11.6 versus 8. 1, Fl,213 = 6.4 1, P = 0.01), with a significant in teraction (p < 0.03) between these factors. Pulse, although significantly elevated by hypercapnia (5.5 beats per minute), showed no significant effects of hypertension and only a marginal significance of CO2 concentration (Fl,194 = 3.70, P < 0.06).
During the hypercapnic procedure, CO2 inhala tion was occasionally discontinued for reasons of patient request or safety as defined in the methods section. This occurred in 15 of 200 procedures for the 4% group (9 for dyspnea, 1 for malaise, and 5 for hypertension), and 9 of 17 procedures for the 6% group (5 for dyspnea and 4 for hypertension) (p < 0.000 1). The time of discontinuation after beginning CO2 was not significantly different between the 4 and 6% groups (7.8 ± 2.3 min versus 6.3 ± 2.6 min).
DISCUSSION
Acute adverse effects of CO2 are theoretically at tributable to its direct CNS actions, its respiratory effects, and its effects on the cardiac and cerebral vascular beds. Carbon dioxide can induce anxiety and other subjective complaints, especially in pa tients with panic disorder (Gorman et al., 1988) . This effect is related to both the percent CO2 in haled and the final Petco2 achieved. Many prior studies used CO2 concentrations of 5-14% with re sulting P aco2 of up to 101 mm Hg; in the present series, the highest Petco2 achieved with 4% was 54 (mean 43), whereas for 6% it was 58 (mean 53). We found the number of complaints requiring discon tinuation to be only 5% in the 4% CO2 group but 29% in the 6% group, consistent with the effects of higher inhaled concentration.
In isolated preparations, CO2 produces vasodila tion of most vascular beds and is a negative inotro pic agent (Price, 1960; Sechzer et aI., 1960; Cullen and Eger, 1974) . However, through its effects on the central nervous system it evokes sympathoad renal responses, resulting in a net increase in myo cardial contractility, heart rate, and blood pressure (Price, 1960; Sechzer et aI., 1960; Cullen and Eger, 1974) . Therefore, CO2 challenge could alter myo cardial oxygen demand, produce arrhythmias, or result in excessive hypertension, but the risk of myocardial ischemia appears to be small. Hard grove et al. (1938) , studied 30 patients (age 21-60 years) with hypertension, who inhaled a 10% CO2/ 90% O2 mixture for 5 min. No symptoms of isch emia were described, despite blood pressures as high as 245/130. Rasmussen et al. (1978) studied 12 patients (ages 45-79 years) undergoing carotid end arterectomy. Patients were New York Heart Asso ciation (NYHA) class II or III and had a history of hypertension (n = 5), arrhythmias (n = 3), conges tive heart failure (n = 3), myocardial infarction and angina (n = 6), or cardiomegaly (n = 8). Myocar dial oxygen balance (EVR) was assessed by systolic time interval measurements. A P aco2 between 37 and 50, although slightly lowering EVR, did not cause this index to approach levels that could be associated with ischemia. Only at a P aco2 of at least 20.8 ± 12.9 12 ± 13.9 7.8 ± 10.6 8.8 ± 8.9 (n = 6) 11.6 ± 12,SC 10.3 ± 10.9c (n = II) � SBP, change in systolic blood pressure; � DBP, change in diastolic blood pressure; + HTN, with hypertension; -HTN, without hypertension.
Significance compared with baseline for that condition: up < 0.0001, b p < 0.001, cp < 0.01. d Significantly different from 6% CO2 (p < 0.05).
56 torr was the EVR at an ischemic level. Although safety considerations under anesthesia differ from the current series, this level of P aco2 was never reached in our 4% procedures, but was occasionally seen with 6% CO2, Complaints of dyspnea, al though possibly representing an "a nginal equivalent," always promptly resolved « 1 min) with discontinuation of CO2, In the absence of other arrhythmogenic factors, CO2 is an unusual cause of cardiac ectopy even up to a P aco2 of at least two times normal (Price, 1960; Sechzer et aI., 1960) . Al though arrhythmias were not directly assessed in the present series, none of our patients complained of palpitations or had changes in vital signs sugges tive of serious ventricular ectopy. The hypertensive effects of CO2 are normally mit igated by the autoregulatory capacity of the cere brovascular circulation. Despite blood pressure in creases greater than in our patients, and docu mented dysautoregulation, no cerebrovascular complications occurred in previous series (Agnoli et aI., 1968; Fieschi et aI., 1968; Olesen, 1973; Strandgaard et aI., 1973) . We found a greater hy pertensive response to CO2 in association with hy pertension, a phenomenon previously reported by Hardgrove (1938) ; however, the limits of autoregu lation shift upward in chronic hypertension (Strandgaard et aI., 1973) . Thus in our series there was no relationship between reactivity, the occur rence of adverse events, and changes in blood pres sure. In the 10 patients we studied with arteriove nous malformations (A VMs), there were no signif icant adverse effects of CO2, Szabo et al. (1989) studied 56 A VMs; despite average increases in SBP of 44 mm Hg, and MABP of 32 mm Hg, there was no occurrence of spontaneous rupture. Brown et al. (1988) followed 168 patients with unruptured intra cranial AVMs for a mean of 8.2 years. Hemorrhage occurred in 31 patients but was not significantly as sociated with a history of hypertension. We did not study patients with unclipped aneurysms; given the possible association between aneurysm rupture and exertion, we would suggest caution in the use of CO2 in such patients.
Although we did not explicitly study the respira tory actions of CO2, some patients complained of difficulty breathing. Given a normal minute ventila tion of 7-8 Llmin, inhalation of 4% CO2 results in almost a doubling of this value, whereas 6% causes an increase to �33 Llmin. Both increases are far less, however, than either a subject's maximum breathing capacity, or even the respiratory effort associated with vigorous muscular exercise (Dripps and Comroe, 1947; Ganong, 1975) .
Finally, there is the theoretic risk of symptomatic steal, where normal reactivity of other tissue results in an actual decline in flow to the diseased area. In our series, there were 11 patients in the 4% group with globally negative reactivity (absolute: -0.3 1 ± 0.25; relative: -0.59% ± 0.34) and one patient in the 6% group (absolute: -0.63; relative: -1.39%). These patients represented a range of possible pa thologies including sickle cell disease (n = 2), oc clusive cerebrovascular disease (n = 8), dementia (n = 1), and attention deficit disorder (n = 1). Al though regional rather than global reactivities are probably more important determinants of local en ergy balance, none of these patients experienced clinically apparent neurologic ischemic phenome non. Only one patient in the current series had tran sient neurological symptoms. He was a 72-year-old man with long-standing hypertension, intermittent left sided transient ischemic attacks, and a fluctu ating symptomatic course while in the hospital. His normocapnic perfusion was markedly low (M2 lSI 29 right, 33 left). Hypercapnia was aborted 1 min after Xe inhalation, when he complained of left up per extremity numbness and weakness. His Pet cO2 rose only by 8 mm Hg (30.2-38.2), and blood pres sure rose by 12/8 from a baseline of 138/80. His global reactivity was positive, but reactivity was significantly lower in the right hemisphere and local steal was observed in right perirolandic regions. His symptoms resolved within 10 min following discon tinuation of hypercapnia. The only alternative to hypercapnia for testing of cerebrovascular reserve is acetazolamide (Bogsrud et aI., 1990) . In the doses commonly employed (up to 1,000 mg), acetazolamide is a more potent va sodilator than even 6% CO2, and thus may be useful for delineation of subtle abnormalities. It also pre sents with a different safety profile, and lacks sev eral of the contraindications for hypercapnia. In our experience, it is useful in those few cases where CO2 is clearly contraindicated or those that require maximal vasodilation to elicit perfusion abnormal ity. We do not use it routinely, however, due to its irreversibility. Whereas the effects of CO2 disap pear within seconds after discontinuation, there is no established method of reversing acetazolamide, once injected.
Based on our clinical experience and the theoret ical considerations discussed above we conclude that hypercapnic stimulation with low concentra tions of CO2 is a safe procedure (using our a priori exclusion criteria to eliminate the highest risk pa tients). Furthermore, because adverse effects, but not CBF reactivity, are related to inhaled CO2 con centration, we suggest the use of 4% CO2 for most procedures. We also suggest specific guidelines for Despite the lack of positive evidence, we consider the following to be relative contraindications for hypercapnia Recent (within one month) intracerebral hematoma or hemorrhagic infarction. Known presence of an un clipped cerebral aneurysm. Unstable cerebrovascular syndromes, with new deficits within 48 h. Prior history of malignant cardiac arrhythmias (i.e., ventricular fibrillation or tachycardia, or complete heart block with no pacemaker). Unstable angina, or known intolerance to minimal exercise. Resting systolic blood pressure> 200 mm Hg. Severe chronic obstructive pulmonary disease (P ac02 >50 or oxygen use).
When hypercapnia is used, we recommend monitoring of clinical status (including encouraging the patient to report any symptoms or discomfort), and vital signs. In addition, hypercapnia should probably be terminated on occurrence of the following Any complaint by the patient of excessive discomfort. Appearance of a new neurologic deficit. Systolic pressure >50-55 mm Hg or MABP >35-40 mm Hg above normocapnic levels, or pulse acceleration over baseline of 30-40 beats per minute.
the use of CO2, particularly in populations at risk for serious events (see Table 4 ). These conservative guidelines should be viewed only as relative con traindications, however, and the final decision whether to administer CO2 must follow a careful review of the risk/benefit ratio.
